Hansa Biopharma half year report 2023 : vimarsana.com

/PRNewswire/ -- Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and...

Related Keywords

United States , Belgium , Berlin , Germany , Australia , Sweden , Netherlands , Finland , France , United Kingdom , American , Australian , Prnewswire Hansa Biopharma , Donato Spota , Hansa Biopharma , Matthew Shaulis , Philipp Enghard , Adrian Schreiber , Stephanie Kenney , Klaus Sindahl , Australian Therapeutic Goods Administration , American Society Of Gene , Vp Global Corporate Affairs , Acceptable Mismatch Program , Acceptable Mismatch , American Society , Cell Therapy Conference , Duchenne Muscular , Lead Nicer , Crigler Najjar Phase , Interim Report , Full Year Report , Annual Report , Interim Report January , Half Year Report January , Thursday July , Securities Markets , Hansa Biopharma Ab ,